This Article Full Text (PDF) All Versions of this Article: 0269881107082119v1 22/3/254    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Curtis, V. Articles by Sacchetti, E. Search for Related Content PubMed PubMed Citation Articles by Curtis, V. Articles by Sacchetti, E. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Psychotic Disorders Social Bookmarking                   What's this?

Long-acting risperidone improves negative symptoms in stable psychotic patients

Institute of Psychiatry, Maudsley Hospital, London, UK

K. Katsafouros

Tarsi Psychiatric Clinic, Psychotherapeutic Center, Dromokaition State Hospital, Athens, Greece

H-J. Möller

Department of Psychiatry, University of Munich, Munich, Germany

R. Medori

Janssen-Cilag, Medical Affairs EMEA, Beerse, Belgium

E. Sacchetti

University Psychiatric Unit, Brescia University School of Medicine and Department of Mental Health, Brescia Spedali Civili, Brescia, Italy

The aim of this paper was to evaluate the efficacy of risperidone long-acting injectable (RLAI) for reducing negative symptoms of schizophrenia in patients with predominantly negative symptoms at baseline. A subanalysis was performed on data from the 6-month, open-label Switch to Risperidone Microspheres trial. Patients with Positive and Negative Syndrome Scale (PANSS) negative subscale score 21, which was higher than their PANSS positive subscale score, were included in this subanalysis. Improvement in negative symptoms was measured by assessing change in the PANSS negative subscale and a negative factor score. Additional outcome variables included measures in general functioning, quality of life and patient satisfaction. A total of 842 patients were eligible for inclusion in this subanalysis. Six months of treatment was completed by 631 (74.9%) patients. Forty-three (5.1%) patients discontinued treatment due to an adverse event. Negative symptoms were significantly reduced by 6.1 ± 6.3 points for the PANSS negative score and 6.1 ± 6.4 points for the negative factor score (P < 0.0001 for both). Significant improvements were also noted for total PANSS and other PANSS subscale scores, general functioning, quality of life and patient satisfaction (P < 0.0001). The most common treatment-emergent adverse events (>5%) were: anxiety (6.8% of patients), exacerbation of disease (6.2%) and insomnia (5.7%). Overall, RLAI was well tolerated and associated with significant reductions in movement disorder severity. The treatment resulted in a significant improvement in negative symptom severity and was well tolerated in patients with predominantly negative symptoms, who switched from a stable antipsychotic regimen.

Key Words: risperidone • schizophrenia • long-acting • atypical antipsychotic • negative symptoms

This version was published on May 1, 2008

Journal of Psychopharmacology, Vol. 22, No. 3, 254-261 (2008)
DOI: 10.1177/0269881107082119


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?